Login to Your Account



No Cash? No Problem

Diagnostics Firms Flexible in Forming Biotech RxDx Deals

By Trista Morrison
Editor

Tuesday, February 21, 2012

Melanoma drug Zelboraf (vemurafenib, Daiichi Sankyo Co. Ltd. and Roche AG) and lung cancer drug Xalkori (crizotinib, Pfizer Inc.) proved incorporating a companion diagnostic early in clinical development can save time and money: Both drugs advanced from Phase I to FDA approval in five years. (See BioWorld Insight, Sept. 6, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription